{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    62,
    65,
    73,
    74,
    79,
    88,
    89,
    90,
    93,
    94,
    95,
    146,
    113,
    116,
    123
  ],
  "modelUsed": "gemini-3-flash",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "first dose of study drug",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "Baseline Visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "screening period",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_9",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_15",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_daily_94",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "Screening period"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "follow-Up Period"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "P260W",
        "interval": "P1D",
        "minObservations": 1820,
        "exitCondition": "Completion of Period 2 (246 weeks) or failure to show 20% improvement in TJC/SJC at 2 consecutive visits after Week 26",
        "sourceText": "1 tablet once daily (upadacitinib or matching placebo) to maintain blinding."
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P7D",
        "minObservations": 14,
        "exitCondition": "End of Period 1",
        "sourceText": "Each subject will be instructed to take a required number of capsules once weekly (MTX and/or matching placebo)"
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P1D",
        "minObservations": 98,
        "exitCondition": "End of Period 1",
        "sourceText": "all subjects should take a dietary supplement of folic acid (or equivalent) throughout Period 1 participation"
      },
      {
        "id": "rep_llm_4",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P14W",
        "interval": "P14W",
        "minObservations": 1,
        "exitCondition": "Completion of Week 14 visit",
        "sourceText": "a 14-week randomized, double-blind, parallel-group, controlled treatment period (Period 1)"
      },
      {
        "id": "rep_llm_5",
        "type": "Cycle",
        "startOffset": "P14W",
        "endOffset": "P260W",
        "interval": "P246W",
        "minObservations": 1,
        "exitCondition": "Completion of 246 weeks",
        "sourceText": "a 246-week blinded extension period (Period 2)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "Period 1 and Period 2"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "PERIOD_1_TREATMENT",
          "PERIOD_2_LONG_TERM_EXTENSION",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Baseline",
          "Week 14",
          "End of Study",
          "Safety Follow-up",
          "Screening",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'If subject experiences gastrointestinal perforation (excluding appendicitis/mechanical injury)', 'path': ['IMMEDIATE_DISCONTINUATION', 'EARLY_TERMINATION_VISIT']}, {'condition': 'If subject experiences confirmed ALT or AST > 8 x ULN', 'path': ['STUDY_DRUG_INTERRUPTION', 'MEDICAL_DIRECTOR_CONSULTATION']}, {'condition': 'State of emergency or pandemic (e.g., COVID-19)', 'path': ['HOME_HEALTHCARE_VISITS', 'LOCAL_LAB_TESTING', 'DIRECT_TO_PATIENT_SHIPMENT']}, {'condition': 'Completion of Period 1', 'path': ['PERIOD_2_LONG_TERM_EXTENSION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Sign",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 3"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "X-Ray",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 4"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3; SINGLE signals: 3"
      },
      {
        "activityId": "Patient's Assessment of Severity and Duration of Morning Stiffness Numerical Rating Scale",
        "executionType": "Single",
        "rationale": "The protocol specifies this questionnaire is collected at scheduled intervals until Week 276, indicating a recurring visit-based assessment."
      },
      {
        "activityId": "TB (tuberculosis) Testing/TB Prophylaxis",
        "executionType": "Single",
        "rationale": "The text mentions 'annual TB test', which indicates a scheduled repeat assessment at specific study intervals."
      },
      {
        "activityId": "Chest X-rays (CXR)",
        "executionType": "Single",
        "rationale": "The protocol describes a conditional workflow where CXR may be required based on an investigator's determination of safety or specific triggers like seroconversion."
      },
      {
        "activityId": "Study Visits (Virtual or Alternative)",
        "executionType": "Single",
        "rationale": "The use of virtual/alternative locations is an ordered conditional workflow triggered by specific decision points such as a pandemic or state of emergency."
      },
      {
        "activityId": "Outcomes and Questionnaires",
        "executionType": "Single",
        "rationale": "The protocol indicates these are completed at feasible visits, implying they are part of the standard scheduled study visit activities."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "Period 1 and Period 2"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. If a subject prematurely discontinues study participation (withdrawal of informed consent), the procedures outlined for the Premature Discontinuation visit (PD visit) should be completed as soon as possible, preferably within 2 weeks of study drug discontinuation.",
        "footnoteId": "fn_1",
        "structuredCondition": "event.premature_discontinuation == true",
        "appliesToActivityIds": [
          "Premature Discontinuation visit procedures"
        ],
        "sourceText": "a. If a subject prematurely discontinues study participation (withdrawal of informed consent), the p"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. The Baseline visit procedures will serve as the reference for all subsequent visits with the exception of the ECG which will be obtained at Screening only and used as the baseline reference.",
        "footnoteId": "fn_2",
        "structuredCondition": "activity.ECG.baseline_reference == screening_only",
        "appliesToActivityIds": [
          "ECG",
          "Baseline visit procedures"
        ],
        "sourceText": "b. The Baseline visit procedures will serve as the reference for all subsequent visits with the exce"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. This visit is 30 days after last dose of study drug for those subjects who complete Period 1 and do NOT enter Period 2. A 30-day follow-up phone call may be allowed for subjects who have completed PD visit to determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs.",
        "footnoteId": "fn_3",
        "structuredCondition": "subject.period_2_entry == false",
        "appliesToActivityIds": [
          "Follow-up visit",
          "Follow-up phone call"
        ],
        "sourceText": "c. This visit is 30 days after last dose of study drug for those subjects who complete Period 1 and "
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. Informed consent should be obtained at Screening prior to performing any study related procedures.",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.before(informed_consent, all_procedures)",
        "appliesToActivityIds": [
          "Informed consent",
          "Screening procedures"
        ],
        "sourceText": "d. Informed consent should be obtained at Screening prior to performing any study related procedures"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. Document herpes zoster and hepatitis B vaccination status in medical history.",
        "footnoteId": "fn_5",
        "sourceText": "e. Document herpes zoster and hepatitis B vaccination status in medical history."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_before",
        "text": "f. Collect serious adverse events and protocol-related nonserious AEs that occur after a subject signs the informed consent, prior to the first dose of study drug.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.between(informed_consent, first_dose)",
        "appliesToActivityIds": [
          "AE collection",
          "SAE collection"
        ],
        "sourceText": "f. Collect serious adverse events and protocol-related nonserious AEs that occur after a subject sig"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "g. Prior to other procedures. For morning stiffness, duration will be captured only if NRS rating is > 0.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.before(morning_stiffness, other_procedures) && morning_stiffness.nrs > 0",
        "appliesToActivityIds": [
          "Morning stiffness duration"
        ],
        "sourceText": "g. Prior to other procedures. For morning stiffness, duration will be captured only if NRS rating is"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. Refer to Section 5.3.1.1 Study Procedures TB Testing for specific requirements for TB testing and TB prophylaxis.",
        "footnoteId": "fn_8",
        "sourceText": "h. Refer to Section 5.3.1.1 Study Procedures TB Testing for specific requirements for TB testing and"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. The chest x-ray will not be required if a subject had a previous normal chest-x-ray within 90 days of Screening, provided that all source documentation is available at the site (refer to Section 5.3.1.1 Chest X-Ray for specific requirements).",
        "footnoteId": "fn_9",
        "structuredCondition": "subject.previous_normal_chest_xray.timing <= P90D",
        "appliesToActivityIds": [
          "Chest x-ray"
        ],
        "sourceText": "i. The chest x-ray will not be required if a subject had a previous normal chest-x-ray within 90 day"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "eligibility_condition",
        "text": "j. For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided all source documentation is available. Refer to Section 5.3.1.1 12-Lead ECG for additional details.",
        "footnoteId": "fn_10",
        "structuredCondition": "subject.previous_normal_ecg.timing <= P90D",
        "appliesToActivityIds": [
          "ECG"
        ],
        "sourceText": "j. For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will "
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "k. For subjects who do not enter Period 2 or prematurely discontinue from the study, an ECG will be performed.",
        "footnoteId": "fn_11",
        "structuredCondition": "subject.period_2_entry == false || subject.premature_discontinuation == true",
        "appliesToActivityIds": [
          "ECG"
        ],
        "sourceText": "k. For subjects who do not enter Period 2 or prematurely discontinue from the study, an ECG will be "
      },
      {
        "id": "fn_cond_12",
        "conditionType": "timing_before",
        "text": "l. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.",
        "footnoteId": "fn_12",
        "structuredCondition": "timing.before(vital_signs, blood_draws)",
        "appliesToActivityIds": [
          "Blood pressure",
          "Pulse rate",
          "Body temperature",
          "Respiratory rate"
        ],
        "sourceText": "l. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blo"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "procedure_conditional",
        "text": "m. A full physical exam is required at the visits indicated. A symptom-directed physical exam may be performed when necessary.",
        "footnoteId": "fn_13",
        "sourceText": "m. A full physical exam is required at the visits indicated. A symptom-directed physical exam may be"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "n. For all women of childbearing potential, collect serum for pregnancy test only at screening. If serum pregnancy test comes back borderline, a repeat test is necessary (pregnancy is an exclusion criterion). Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.",
        "footnoteId": "fn_14",
        "structuredCondition": "subject.sex == female && subject.childbearing_potential == true",
        "appliesToActivityIds": [
          "Serum pregnancy test"
        ],
        "sourceText": "n. For all women of childbearing potential, collect serum for pregnancy test only at screening. If s"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o. For all women of childbearing potential, collect urine for pregnancy test at Baseline and all subsequent visits. If urine pregnancy test is negative, begin or continue dosing. If urine pregnancy test is positive, withhold dosing and perform a serum pregnancy test. Pregnant subjects must discontinue from study drug. Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.",
        "footnoteId": "fn_15",
        "sourceText": "o. For all women of childbearing potential, collect urine for pregnancy test at Baseline and all sub"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "eligibility_exclusion",
        "text": "p. In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. For safety evaluations of signs and symptoms of infection and management of adverse events, the investigator may locally test procalcitonin. Results of tests such as hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting the clinical utility of these tests in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to Investigator, study site personnel, and the subject.",
        "footnoteId": "fn_16",
        "sourceText": "p. In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "procedure_conditional",
        "text": "q. Minimum 8-hour fast. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.",
        "footnoteId": "fn_17",
        "structuredCondition": "subject.fasting_status == true",
        "appliesToActivityIds": [
          "Fasting labs"
        ],
        "sourceText": "q. Minimum 8-hour fast. If a subject is not able to fast when necessary, due to unforeseen circumsta"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "r. A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all required visits. A microscopic analysis will be performed in the event the dipstick results show leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.",
        "footnoteId": "fn_18",
        "structuredCondition": "dipstick.leukocytes > 0 || dipstick.nitrite > 0 || dipstick.protein > 0 || dipstick.ketones > 0 || dipstick.blood > 0 || dipstick.glucose > normal",
        "appliesToActivityIds": [
          "Microscopic urinalysis"
        ],
        "sourceText": "r. A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all requir"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "s. FSH should be tested at Screening if the female subject is < 55 years of age AND has had no menses for ≥ 12 months AND has no history of permanent surgical sterilization (defined in Section 5.2.4).",
        "footnoteId": "fn_19",
        "structuredCondition": "subject.sex == female && subject.age < 55 && subject.menses_absent_duration >= P12M && subject.surgical_sterilization == false",
        "appliesToActivityIds": [
          "FSH test"
        ],
        "sourceText": "s. FSH should be tested at Screening if the female subject is < 55 years of age AND has had no mense"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "procedure_conditional",
        "text": "t. Anti-HIV Ab will be performed at Screening, unless prohibited by local regulations. The Investigator must discuss any local reporting requirements to local health agencies with the subject. The site will report confirmed positive results to their health agency per local regulations, if necessary. If a subject has a confirmed positive result, the Investigator must discuss with the subject the potential implications to the subject's health and subject should receive or be referred for clinical care promptly. A subject will not be eligible for study participation if test results indicate a positive HIV infection. AbbVie will not receive results from the testing and will not be made aware of any positive result.",
        "footnoteId": "fn_20",
        "sourceText": "t. Anti-HIV Ab will be performed at Screening, unless prohibited by local regulations. The Investiga"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "timing_before",
        "text": "u. At Week 2 and Week 4 visits, PK samples should be collected prior to dosing and the subjects should take the study drug dose at the clinic after collecting the PK blood sample. However, if the subject normally takes the study drug dose at a time that is after the time of the scheduled study visit, the subject should follow the regular dosing schedule and the PK sample should be collected at any time during the visit.",
        "footnoteId": "fn_21",
        "structuredCondition": "timing.before(pk_sample, dose) || (subject.dosing_schedule > visit_time && timing.anytime(pk_sample))",
        "appliesToActivityIds": [
          "PK samples"
        ],
        "sourceText": "u. At Week 2 and Week 4 visits, PK samples should be collected prior to dosing and the subjects shou"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "v. PK samples should be collected at any time during the visit. Subject should follow the regular dosing schedule.",
        "footnoteId": "fn_22",
        "sourceText": "v. PK samples should be collected at any time during the visit. Subject should follow the regular do"
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "w. Samples only collected if subject provides written consent.",
        "footnoteId": "fn_23",
        "structuredCondition": "subject.optional_consent == true",
        "appliesToActivityIds": [
          "Optional samples"
        ],
        "sourceText": "w. Samples only collected if subject provides written consent."
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "x. For subjects entering Period 2.",
        "footnoteId": "fn_24",
        "sourceText": "x. For subjects entering Period 2."
      },
      {
        "id": "fn_cond_25",
        "conditionType": "general",
        "text": "1. Have you or an immediate family member or other close contact ever been diagnosed or treated for tuberculosis?",
        "footnoteId": "fn_25",
        "sourceText": "1. Have you or an immediate family member or other close contact ever been diagnosed or treated for "
      },
      {
        "id": "fn_cond_26",
        "conditionType": "timing_after",
        "text": "2. Have you lived in or had prolonged travels to countries in the following regions: ● Sub-Saharan Africa ● India ● China ● Mexico ● Southeast Asia or Micronesia ● The former Soviet Union",
        "footnoteId": "fn_26",
        "sourceText": "2. Have you lived in or had prolonged travels to countries in the following regions: ● Sub-Saharan A"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "3. Have you lived or worked in a prison, homeless shelter, immigration center, or nursing home?",
        "footnoteId": "fn_27",
        "sourceText": "3. Have you lived or worked in a prison, homeless shelter, immigration center, or nursing home?"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "timing_after",
        "text": "4. Have you, or an immediate family member, had any of the following problems for the past 3 weeks or longer: ● Chronic Cough ● Production of Sputum ● Blood-Streaked Sputum ● Unexplained Weight Loss ● Fever ● Fatigue/Tiredness ● Night Sweats ● Shortness of Breath From: http://www.mayoclinic.com/health/tuberculosis/DS00372/DSECTION=risk-factors http://www.in.gov/fssa/files/Tuberculosis_Questionnaire.pdf obbvie",
        "footnoteId": "fn_28",
        "sourceText": "4. Have you, or an immediate family member, had any of the following problems for the past 3 weeks o"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: ACR20 Response (US/FDA)",
        "endpointType": "Primary",
        "inputs": [
          "Tender Joint Count (TJC)",
          "Swollen Joint Count (SJC)",
          "Patient's Assessment of Pain (VAS)",
          "Patient's Global Assessment of Disease Activity (VAS)",
          "Physician's Global Assessment of Disease Activity (VAS)",
          "Health Assessment Questionnaire Disability Index (HAQ-DI)",
          "hsCRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Week 14"
        },
        "algorithm": "(TJC_improvement >= 20%) AND (SJC_improvement >= 20%) AND (count(improvement >= 20% in [Pain_VAS, Pt_Global_VAS, Phys_Global_VAS, HAQ-DI, hsCRP]) >= 3)",
        "successCriteria": "20% or greater improvement in TJC and SJC and >= 3 of the 5 additional measures",
        "sourceText": "ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual A"
      },
      {
        "id": "ep_2",
        "name": "Primary: Low Disease Activity (EU/EMA)",
        "endpointType": "Primary",
        "inputs": [
          "DAS28",
          "CRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Week 14"
        },
        "algorithm": "DAS28(CRP) <= 3.2",
        "successCriteria": "DAS28 (CRP) score less than or equal to 3.2",
        "sourceText": "LDA is defined as Disease Activity Score (DAS) 28 (C-reactive protein [CRP]) ≤ 3.2."
      },
      {
        "id": "ep_3",
        "name": "Key Secondary: Change from baseline in DAS28 (CRP)",
        "endpointType": "Secondary",
        "inputs": [
          "DAS28(CRP)_Baseline",
          "DAS28(CRP)_Week14"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Week 14"
        },
        "algorithm": "DAS28(CRP)_Week14 - DAS28(CRP)_Baseline",
        "successCriteria": "Mean change from baseline",
        "sourceText": "Change from baseline in DAS28 (CRP)"
      },
      {
        "id": "ep_4",
        "name": "Key Secondary: Clinical Remission (CR)",
        "endpointType": "Secondary",
        "inputs": [
          "DAS28(CRP)"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Week 14"
        },
        "algorithm": "DAS28(CRP) < 2.6",
        "successCriteria": "DAS28 (CRP) score less than 2.6",
        "sourceText": "Proportion of subjects achieving Clinical remission (CR) based on DAS28 (CRP)... CR < 2.6"
      },
      {
        "id": "ep_5",
        "name": "Secondary: ACR50 Response Rate",
        "endpointType": "Secondary",
        "inputs": [
          "TJC",
          "SJC",
          "Pain_VAS",
          "Pt_Global_VAS",
          "Phys_Global_VAS",
          "HAQ-DI",
          "hsCRP"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Week 14"
        },
        "algorithm": "(TJC_improvement >= 50%) AND (SJC_improvement >= 50%) AND (count(improvement >= 50% in [Pain_VAS, Pt_Global_VAS, Phys_Global_VAS, HAQ-DI, hsCRP]) >= 3)",
        "successCriteria": "50% or greater improvement in required components",
        "sourceText": "ACR50 response rate"
      },
      {
        "id": "ep_6",
        "name": "Secondary: HAQ-DI Clinically Meaningful Response",
        "endpointType": "Secondary",
        "inputs": [
          "HAQ-DI_Baseline",
          "HAQ-DI_Current"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "All visits"
        },
        "algorithm": "(HAQ-DI_Current - HAQ-DI_Baseline) <= -0.22",
        "successCriteria": "Reduction in HAQ-DI score of 0.22 or greater",
        "sourceText": "Proportion of subjects with change from baseline in HAQ-DI ≤ –0.22"
      },
      {
        "id": "ep_7",
        "name": "Secondary: SDAI Low Disease Activity",
        "endpointType": "Secondary",
        "inputs": [
          "SDAI"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "All visits"
        },
        "algorithm": "SDAI <= 11.0",
        "successCriteria": "SDAI score less than or equal to 11.0",
        "sourceText": "SDAI LDA ≤ 11.0"
      },
      {
        "id": "ep_8",
        "name": "Secondary: CDAI Clinical Remission",
        "endpointType": "Secondary",
        "inputs": [
          "CDAI"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "All visits"
        },
        "algorithm": "CDAI <= 2.8",
        "successCriteria": "CDAI score less than or equal to 2.8",
        "sourceText": "CDAI CR ≤ 2.8"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from baseline in DAS28 (CRP)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "Visit_value - Baseline_value",
        "baselineDefinition": "Value at Baseline Visit (Day 1)",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 14, Week 20, Week 26, Week 36, Week 48, every 12 weeks through Week 240, and Week 260/PD",
        "imputationRule": "Not explicitly stated for all endpoints; MMRM implied for continuous changes",
        "unit": "Score"
      },
      {
        "id": "dv_2",
        "name": "Low Disease Activity (LDA) based on DAS28 (CRP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "If DAS28 (CRP) <= 3.2 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable for status at visit",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 14 and subsequent Period 2 visits",
        "imputationRule": "Not specified",
        "unit": "Boolean"
      },
      {
        "id": "dv_3",
        "name": "Clinical Remission (CR) based on DAS28 (CRP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "DAS28 (CRP)"
        ],
        "derivationRule": "If DAS28 (CRP) < 2.6 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 14 and subsequent Period 2 visits",
        "imputationRule": "Not specified",
        "unit": "Boolean"
      },
      {
        "id": "dv_4",
        "name": "ACR20/50/70 response rate",
        "variableType": "Composite",
        "sourceVariables": [
          "TJC",
          "SJC",
          "Patient Global Assessment",
          "Physician Global Assessment",
          "Pain",
          "HAQ-DI",
          "CRP/ESR"
        ],
        "derivationRule": "At least 20%/50%/70% improvement in TJC and SJC AND 20%/50%/70% improvement in 3 of the 5 remaining ACR core set measures",
        "baselineDefinition": "Baseline Visit values",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 14, Week 20, Week 26, Week 36, Week 48, every 12 weeks through Week 240, and Week 260/PD",
        "imputationRule": "Not specified",
        "unit": "Rate"
      },
      {
        "id": "dv_5",
        "name": "Change from baseline in HAQ-DI",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "HAQ-DI"
        ],
        "derivationRule": "Visit_value - Baseline_value",
        "baselineDefinition": "Value at Baseline Visit",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 14",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_6",
        "name": "Proportion of subjects with change from baseline in HAQ-DI <= -0.22",
        "variableType": "Categorical",
        "sourceVariables": [
          "HAQ-DI"
        ],
        "derivationRule": "If (Visit_value - Baseline_value) <= -0.22 then 'Responder' else 'Non-responder'",
        "baselineDefinition": "Value at Baseline Visit",
        "baselineVisit": "Baseline",
        "analysisWindow": "All visits",
        "imputationRule": "Not specified",
        "unit": "Proportion"
      },
      {
        "id": "dv_7",
        "name": "Percent improvement in TJC and SJC",
        "variableType": "PercentChange",
        "sourceVariables": [
          "TJC",
          "SJC"
        ],
        "derivationRule": "((Visit_value - Baseline_value) / Baseline_value) * 100",
        "baselineDefinition": "Value at Baseline Visit",
        "baselineVisit": "Baseline",
        "analysisWindow": "Starting at Week 26 and thereafter (Rescue/Discontinuation criteria)",
        "imputationRule": "Not specified",
        "unit": "%"
      },
      {
        "id": "dv_8",
        "name": "Low Disease Activity (LDA) based on CDAI",
        "variableType": "Categorical",
        "sourceVariables": [
          "CDAI"
        ],
        "derivationRule": "If CDAI <= 10 then 'Yes' else 'No'",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 26 (Rescue assessment)",
        "imputationRule": "Not specified",
        "unit": "Boolean"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Period 1 Treatment",
        "Period 2 Long Term Extension",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Period 1 Treatment",
          "trigger": "Progress to Period 1 Treatment"
        },
        {
          "fromState": "Period 1 Treatment",
          "toState": "Period 2 Long Term Extension",
          "trigger": "Progress to Period 2 Long Term Extension"
        },
        {
          "fromState": "Period 2 Long Term Extension",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Period 1 Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Period 2 Long Term Extension",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Period 1 Treatment": "PERIOD_1_TREATMENT",
        "Period 2 Long Term Extension": "PERIOD_2_LONG_TERM_EXTENSION",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Upadacitinib",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "At least 276 weeks",
        "doseModifications": [
          "Discontinue study drug treatment immediately if subject develops a gastrointestinal perforation (except appendicitis or mechanical injury)",
          "Immediate study drug interruption for confirmed ALT or AST > 8 × ULN",
          "Provisions for study drug interruptions due to COVID-19"
        ],
        "sourceText": "246-week blinded extension period (Period 2); and a 30-day follow-up visit. Subjects who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:  Group 1: Upa"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 35,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening. Subjects must have been on oral or parenteral M"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Specified that questionnaires are not eligible for completion by virtual interview in the event that an onsite visit cannot be performed due to a pandemic or state of emergency and will be completed a"
      },
      {
        "id": "visit_6",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Period 1",
        "sourceText": "will start on their blinded upadacitinib (30 mg QD, 15 mg QD or Placebo QD) dose at Baseline. Also, starting at Baseline, all subjects will discontinue their current MTX treatment and start their blin"
      },
      {
        "id": "visit_13",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "medications through the end of study drug administration: ● Humira® (adalimumab)"
      },
      {
        "id": "visit_5",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "≥12.5 mg/week] for at least 4 weeks. No MTX washout is needed prior to randomization. All subjects will start on their blinded upadacitinib (30 mg QD, 15 mg QD or Placebo QD) dose at Baseline. Also, s"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Follow-up Visit",
        "targetDay": 30,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_11",
        "visitName": "Week 12",
        "targetDay": 78,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 12,
        "sourceText": "greatest unmet need, the primary endpoint of ACR20 response rate at Week 12 was significantly greater at all doses of upadacitinib (up to 73%) compared with placebo (35%). In addition, numerically hig"
      },
      {
        "id": "visit_8",
        "visitName": "Week 14",
        "targetDay": 92,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 14,
        "epoch": "Period 1",
        "sourceText": "Subjects who complete the Week 14 visit (end of Period 1) will enter the blinded long-term extension portion of the study, Period 2 (246 weeks). Subjects who are assigned to upadacitinib treatment gro"
      },
      {
        "id": "visit_7",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 26,
        "epoch": "Period 2",
        "sourceText": "equivalent) throughout Period 1 participation; while in Period 2 (starting at Week 26) it should only be taken if MTX is given as background medication. Folic acid dosing and timing of regimen should "
      },
      {
        "id": "visit_10",
        "visitName": "Week 48",
        "targetDay": 330,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 48,
        "sourceText": "Week 48 only:  Change from baseline in EQ-5D-5L;"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "and a 30-day follow-up visit. Subjects who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:"
      },
      {
        "id": "visit_9",
        "visitName": "Week 240",
        "targetDay": 1674,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 240,
        "sourceText": "Weeks 20, 26, 36, 48, every 12 weeks through Week 240, and Week 260/PD:  ACR20/50/70 response rates;"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Week 260",
        "targetDay": 1821,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 260,
        "epoch": "Period 2"
      },
      {
        "id": "visit_2",
        "visitName": "Week 276",
        "targetDay": 1926,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 276,
        "epoch": "Period 2",
        "sourceText": "not be collected starting at Week 276 for consistency with footnote \"c.\" of Table 4 \"Study Activities (Period 2).\" ○"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:2:1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "geographic region at screening"
        },
        {
          "id": "strat_llm_1",
          "name": "Main stratification factors",
          "categories": "Not explicitly listed in provided text",
          "isBlocking": false
        }
      ],
      "sourceText": "Upadacitinib\nM15-555 Protocol Amendment 7\nEudraCT 2015-003376-75\n10\nMethodology (Continued):\nThe study duration will include a 35-day screening period; a 14-week randomized, double-blind, \nparallel-gr"
    }
  }
}